Medtronic rapped on the knuckles for improper promotion of device
This article was originally published in Clinica
Medtronic has been accused of improperly promoting its Freestyle Aortic Root Bioprosthesis product, which received FDA approval last November. In a May 12 warning letter from the agency, Medtronic was given 15 working days to correct its promotional material.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.